Receptor-defined subtypes of breast cancer represent distinct cancer types and have differences in risk factors. Whether the two main hormonal forms of oral contraceptives (OCs); i.e. progestin-only (POC) and combined oral contraceptives (COC), are differentially associated with these subtypes are not well known. The aim of our study was to assess the effect of POC and COC use on hormone receptor-defined breast cancer risk in premenopausal women in a prospective population-based cohort -The Norwegian Women and Cancer Study (NOWAC). Information on OC use was collected from 74,862 premenopausal women at baseline. Updated information was applied when follow-up information became available. Multiple imputation was performed to handle missing data, and multivariable Cox regression models were used to calculate hazard ratios (HR) for breast cancer. 1,245 incident invasive breast cancer cases occurred. POC use 5 years was associated with ER1 (HR 5 1.59, 95% CI 1.09-2.32, p trend 5 0.03) and ER1/PR1 cancer (HR 5 1.63, 95% CI 1.07-2.48, p trend 5 0.05), and was not associated with ER2 (p heterogeneity 5 0.36) or ER2/PR2 (p heterogeneity 5 0.49) cancer. COC use was associated with ER2 and ER2/PR2 cancer, but did not increase risk of ER1 and ER1/PR1 cancer. Current COC use gave different estimates for ER/PR-defined subtypes (p heterogeneity 5 0.04). This is the first study to show significant associations between POC use and hormone receptor-positive breast cancer. The lack of power to distinguish effects of POC use on subtype development calls for the need of larger studies to confirm our finding.
Introduction
Breast cancer is the most common cancer in women, and the leading cause of cancer death among females worldwide. 1 Reproductive factors, such as early menarche, late menopause, nulliparity and high age at first birth, are known risk factors for breast cancer. [2] [3] [4] The role of these reproductive factors in breast cancer etiology points toward an essential contributive effect of endogenous female sex hormones in the carcinogenesis of breast tissue. Exogenous female hormones are also associated with breast cancer. In addition to hormone therapy (HT), estrogen-progestin contraceptives (combined oral contraceptives; COCs), are classified as carcinogenic to humans with regards to cervical, breast and liver cancer by the International Agency for Research on Cancer. 5 The association between oral contraceptives (OCs) and breast cancer has been extensively studied for decades. In 1996, a comprehensive pooled analysis of 54 epidemiologic studies found a slightly increased risk of breast cancer associated with current and recent use of COC, and a cessation of risk after 10 years since last use. 6 This has later been confirmed by other studies. [7] [8] [9] [10] Some reports suggest a stronger association between OC use and breast cancer in younger women compared to older women, [11] [12] [13] reflecting the increase in risk associated with recent OC use. Due to a small proportion of women using OCs <10 years before onset of menopause in the NOWAC cohort (<10%), and to the overwhelming evidence of a time-dependent relationship as a function of time since last OC use, 6, 10, 14 i.e. no effect after 10 years since last use, the current article concerns premenopausal women only.
Receptor-defined subtypes of breast cancer represent distinct entities of disease and have differences in risk factors. [15] [16] [17] These subtypes are defined based on the expression of the hormone receptors estrogen receptor (ER) and progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2). Prior studies are inconsistent regarding associations between OC use and risk of receptor-defined subtypes of breast cancer. Some propose that OC use is associated with increased risk of hormone receptor-negative breast cancer, [18] [19] [20] [21] [22] whereas others suggest a decreased risk of hormone receptor-positive cancers by OC use. 21, 23, 24 Conversely, positive associations with ER-positive cancer has been reported 25 as well as no association with either subtype, [26] [27] [28] [29] or similar associations across subtypes. 19, 30 The pooled analysis found no effect of progestin-only contraceptive (POC) use and breast cancer overall. 31 Previous studies on POC and breast cancer are scarce. To date, no study has addressed associations between POC use and subtypes of breast cancer. Norwegian data is suitable for studying POC use due to a substantial amount of users. Thus, the aim of our study was to assess the effect of POC and COC on hormone receptor-defined breast cancer risk in a representative sample of premenopausal Norwegian women.
Materials and Methods

Study population
The Norwegian Women and Cancer Study (NOWAC) is a prospective national population-based cohort of 172,000 Norwegian women. Initiated in 1991, women aged 30-70 were randomly selected by the Central Population Registry and invited to participate. Out of 327,476 invited women in total during the period 1991 to 2007, 172,478 returned a completed questionnaire, providing an overall participation rate of approximately 53%. Statistics Norway substituted identification numbers with serial numbers on the questionnaires. Questionnaire data on lifestyle and health were collected up to three times at 4-to 6-year intervals to provide updated information on exposures. NOWAC has acceptable external validity 32 and has been described in detail elsewhere. 33 For the analyses presented here, 88,258 women who were postmenopausal or 53 years of age or older at baseline were excluded. 34 Additional exclusion criteria: HT-users at baseline (n 5 6,786), prevalent cancers at baseline other than nonmelanoma skin cancer (ICD-10 C44) (n 5 1,018), women who emigrated or died before baseline (n 5 16), women who were 10 years or younger at first birth (n 5 2) and women with missing OC, POC or COC status at baseline (n 5 1,540). This left a total of 74,862 women for the current analyses. Follow-up information from a second questionnaire was collected from 51,850 of these women.
Assessment of OC exposure
Information on exposure to OCs was obtained by selfadministered questionnaires. General questions on OC use were asked, such as ever use, age at first use, duration of use and current use. Furthermore, the women were asked to denote specific periods with OC use, which was defined as any continuous use of one specified OC brand for at least 1 month. To facilitate recall, the questionnaires contained a photo booklet with pictures and names of the different OC brands available on the Norwegian market up to the time of mailing. Up to date, no more than 42 different OC brands have been sold in Norway. We stratified OC use into POC use and COC use based on OC brands used. The internal validity with regard to OC use assessment in NOWAC has been found to be satisfying. 33 
Repeated measurements
Updated information on OC exposure was obtained from follow-up questionnaires. Women who reported ever use at baseline and had missing status or reported never use at followup were categorized as ever users at follow-up. We applied baseline information on OC exposure until follow-up information became available. Women were censored from the study at the time they reached menopause, started using HT, were diagnosed with incident cancer (except non-melanoma skin cancer), died or emigrated, whichever occurred first. All participants were followed-up until December 31, 2015.
Identification of breast cancer cases, death and emigration
The Norwegian 11-digit national identification number, which includes information on date of birth and sex, 35 
Statistical analysis
Repeated measurements of OC, POC and COC use were applied in the analysis of total, ER-defined and ER/PRdefined premenopausal breast cancer. Hazard ratios (HRs) with 95% confidence intervals (CIs) were estimated using Cox proportional hazards models with attained age as the time scale. Separate regression models were constructed for subtype outcomes, allowing women who experienced another subtype than the one defined as failure to be censored at the time when this subtype occurred. 37 Premenopausal breast cancer was defined as incident breast cancer diagnosed prior to or during the same year as the woman's menopause. Age at menopause was set to the given age at which the woman's menstruation stopped. If age at menopause was missing at baseline, we used reported age at menopause from follow-up questionnaires. Women with unknown menopausal status or irregular menses were considered postmenopausal at age 53 or older. This cut-off was based on the definition used in the Million Women Study, 34 and later in the NOWAC study. 38 The multivariable analyses included established or potential risk factors as covariates, which were obtained from the questionnaires. If a linear trend was observed for any covariate, this covariate was treated as continuous. Covariates that changed the regression coefficient with <10% were removed from the model, except for age at menarche. The final multivariable model included the following covariates: BMI (continuous), history of breast cancer in mother (yes, no), age at menarche (continuous), alcohol consumption (0, 0.1-4.9, 5-9.9, 10 g/day) and a combined variable including parity (0, 1, 2, 3 children) and age at first birth (age <25, [25] [26] [27] [28] [29] 30) . For the analysis addressing COC exposure, the model was adjusted for POC use (ever, never), and vice versa.
The HRs of breast cancer subtypes were tested for heterogeneity by the Wald test. For duration variables, heterogeneity between linear trends was tested. All p-values were two-sided. The proportional hazards assumption was evaluated by tests of Schoenfeld residuals and by graphical inspection of a log-log survival plot. All analyses were performed using the statistical package STATA, version 14.
Multiple imputation
Under the assumption that data was missing at random, 39 multiple imputation was used to handle missing information. To reduce sampling variability from the imputation simulations, the missing values were replaced by imputed values from 20 duplicate datasets. 39 The imputation model included all covariates used in the multivariable analyses, age at baseline and follow-up, and the Nelson-Aalen cumulative hazard estimator as predictors.
Two types of missing values occurred due to both item and wave non-response. First, values were missing due to missing information in the questionnaires (item non-response). These included missing covariates at baseline (e.g., alcohol consumption [n 5 1,651], age at menarche [n 5 1,192] and BMI [n 5 1,477]), missing duration of OC use at baseline (n 5 1,180) or follow-up (n 5 23,850), and time since last use at baseline (n 5 1,293) or follow-up (n 5 23,634). Second, missing values at follow-up were due to non-response of a second questionnaire (wave non-response, n 5 23,012). These comprised OC status, POC status and duration and COC status and duration. To avoid possible inconsistencies in status of use at the two points in time, we imputed possible changes in status of OC use and used this information to assign the status at followup as current, former or never use. Similarly, we computed OC duration at follow-up from the imputation of additional use since baseline to avoid lower imputed values at follow-up compared to baseline. 40 The estimates from 20 imputed datasets were combined using Rubin's rules to obtain HRs and corresponding 95% CIs. 41 Sensitivity analysis was conducted to ensure that risk estimates were similar in complete case analysis and multiple imputation analysis.
Ethics NOWAC has been approved by the Regional Committees for Medical and Health Research Ethics (REC) and the Norwegian Data Inspectorate. The participants received written information about the study and future linkages to national registers, along with invitation to receive a second questionnaire. Return of a completed questionnaire was considered consent to participate. A second questionnaire was only sent to participants who had agreed to receive one. Distribution of characteristics at baseline among the study population and premenopausal breast cancer cases is presented in Table 1 . In addition to a larger proportion with familial breast cancer, women who developed premenopausal breast cancer tended to be younger, have lower BMI, lower parity and higher age at first birth compared to the whole cohort.
Results
Current OC use, >10 years duration of OC use and <10 years since last use were associated with premenopausal breast cancer as well as all receptor-defined subtypes (Table 2) , except for current OC use not being associated with ER1/PR1 cancer. >20 years since last use was also associated with ER2/PR2 cancer. In addition, ever and former use of OCs was associated with ER2 and ER2/PR2 breast cancer.
The main findings of our study are presented in Tables 3 and  4 , displaying stratified analysis by POC and COC use. POC use for 5 years or more was associated with ER1 (HR 5 1.59, 95% CI 1.09-2.32) and ER1/PR1 (HR 5 1.63, 95% CI 1.07-2.48) cancer. In women who were POC users and never COC users, the corresponding increase in risk was 1.87 (95% CI 1.21-2.91) for ER1 cancer (Table 4) . However, we observed no significant difference in risk estimates between subtypes with regard to POC use (p ER1 vs. ER2 5 0.36 and p ER1/PR1 vs. ER2/PR2 5 0.49). Ever, current, former and 5 years use of COCs increased the risk of ER2 and ER2/PR2 disease. The risk of ER2/PR2 cancer (HR 5 2.39, 95% CI 1.14-5.04) was significantly different from the risk of ER1/PR1 cancer in current COC users (p heterogeneity 5 0.04).
Supporting Information Table S1 displays the distribution of OC, POC and COC use and missing values among the study population at baseline and follow-up.
Results were similar in the complete case analyses. Stratified analyses on POC and COC use without using multiple imputation (Supporting Information Table S2 ) also indicated positive associations between POC use 5 years and ER1 cancer (HR 5 1.60, 95% CI 1.09-2.35) and ER1/PR1 cancer (HR 5 1.64, 95% CI 1.07-2.51).
Discussion
The main finding of our study was that POC use was associated with hormone receptor-positive premenopausal breast cancer if used for 5 years or more. Thus, our prospective, population-based study has unraveled more exact associations between the main hormonal constituents of OCs and receptor-defined breast cancer risk in premenopausal women. Dissimilar associations between POC and COC use on hormone receptor-defined breast cancer suggest that the exogenous hormones estrogen and progestin might have differential roles in subtype carcinogenesis.
Some of our findings confirm existing knowledge: we have observed that OC use slightly increases risk of premenopausal breast cancer. The increase in risk associated with duration of use could reflect long-term users being more likely to be current or recent users. Although the total risk elevation is modest with regard to ever use (12%), it is noteworthy due to the frequent use of OCs among premenopausal women, making OCs a contributing cause for a substantial number of cases.
Associations between OC use and ER2 or ER2/PR2 breast cancer are in agreement with previous studies. 18, 19, 21, 22 Dolle et al. found increased risk of ER-negative breast cancer with several aspects of OC use (i.e., ever use, duration, age at first use and years since first and last use), while no significant associations were found with ER1 breast cancer. 18 Beaber et al. found significantly increased risks for both ER- 
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Busund et al. The subgroups (i.e., ER1, ER2, ER1/PR1 and ER2PR2) are not mutually exclusive and do not add up to the total amount of cases. 1 Multivariable analysis adjusted for BMI (continuous), history of breast cancer in mother (yes, no), age at menarche (continuous), alcohol consumption (0, 0.1-4.9, 5-9.9, 10 g/day) and a combined variable including parity (0, 1, 2, 3 children) and age at first birth (age <25, 25-29,
30).
2 p-Value, continuous variable. Analyses on POC use are adjusted for COC use in addition to the aforementioned covariates.
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Cancer Epidemiology positive and ER-negative breast cancer with current use and duration of use, 19 as we did in our analysis. When stratifying by hormonal content, POC and COC use were differently associated with hormone receptordefined subtypes. However, heterogeneity tests for POC use were insignificant and unequal associations could be due to a small number of POC users in the hormone receptornegative groups. As limited power is an issue when addressing POC use in relation to hormone receptor-negative cancer, one cannot rule out the possibility that POC use increases risk of this subtype as well. The increased risk of breast cancer provided by POC use is in line with some 9 and in contrast to other studies. 31, 42 Although used as HT, one study found increased risk of breast cancer associated with current use of oral progestins for 4.5 years or more before menopause. 43 These studies have not assessed POC associations in relation to receptor-defined breast cancer.
Our findings further imply that general OC use is also associated with hormone receptor-positive cancers, which is in contrast to most studies. [18] [19] [20] [21] [22] 29 Since POC use has been more common in Scandinavian countries than in the US, 44 a higher portion of POCs in our data could influence OC associations toward hormone receptor-positivity. Previously mentioned studies defined OC use as equivalent to COC use only, 19 ,25 or they did not specify what type of OCs were encompassed as such. 18, 20, 24 Moreover, non-Caucasians are scarce in our cohort which explains the relatively smaller portion of triple-negative cases and consequently hormone receptor-negative cases in our study, as this subtype is more common among AfricanAmerican women. 45 The biological mechanism linking progestin to breast cancer development is a subject of controversy. It is hypothesized that the proliferative effect of progestins on mammary epithelium increase breast cancer risk. 46 Moreover, it has been postulated that in breast cancer cells, crosstalk between the ER and the PR enables PR activation to provide estrogen-mediated proliferative response, 47 which also could influence disease development.
Several challenges arise when studying subtypes of disease. First, the potential of misclassification is noteworthy. Pathologists from wide-ranging laboratories conduct hormone receptor status assays across the country. There is a certain degree of variety in laboratory techniques, scoring methods and interpretation of data. In sum, these represent a subjective influence that opens for the possibility of misclassification. Despite that, studies show satisfactory concordance of hormone receptor status across laboratories with regard to ER1, ER2, ER1/PR1 and ER2/PR2 status, 48 as has been the main classifications used in our study. Moreover, a mixture of 1% and 10% cutoff for ER negativity could dilute associations, as contemporary clinical knowledge recognizes 1% cutoff as true-negative ER expression.
Another major issue involves limited statistical power as we restricted our cohort to premenopausal women and only 14% were diagnosed before menopause. Furthermore, there was a considerable amount of missing receptor status data as cases were diagnosed as of 1991, at which time receptor status testing practices was not standard procedure.
Missing information at baseline and follow-up was imputed, assuming the information was missing at random. This was done to keep observations in the analysis and thus improve the accuracy of associations. In analyses with smaller subgroups, this method improved the precision of the relative risk estimates substantially, without changing their values noteworthy. However, there is a possibility that some information was not missing at random, which would result in obtained estimates not being completely free from bias.
To our knowledge, this is the first study to address associations between POC use and receptor-defined breast cancer. Strengths of our study include its prospective design, avoiding concerns of selection and recall bias, which is a problem for case-control studies of OCs and breast cancer. 49 This inevitable concern was the main purpose of creating the prospective NOWAC study. Moreover, its nationally representative, population-based design allows findings to be generalizable to the whole country or broader. Furthermore, NOWAC is designed to study impact of hormonal constituents on cancer risk by providing reliable and detailed assessment of hormone use. Due to few available OC brands on the Norwegian market, our study has reduced potential of exposure misclassification. Potential exposure misclassification is likely to be non-differential due to the prospective design of the study, and estimates would be biased toward unity. Finally, due to including only premenopausal women in our analysis, we get valid results because risk factors and breast cancer characteristics are dissimilar in pre-and postmenopausal women. 50 Despite numerous strengths of our study, our findings with regard to POC use require further confirmation due to our insignificant heterogeneity tests between subtypes and uncertain biological mechanisms.
